Regulation/Legislation (Health)
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Regulation
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Health & Regulation
Including Oxybenzone, Octinoxate On US Sunscreen Monograph Could Swing On Environmental Impact
FDA will prepare an environmental impact statement on sunscreen ingredients oxybenzone and octinoxate in light of questions on the ingredients’ impact on coral and coral reefs. It plans to complete the review prior to publishing final order for its OTC sunscreen ingredients monograph.
Perrigo’s Latest Brand Buzz: Making, Marketing Burt’s Bees Baby Formula And Supplements
Perrigo’s brand play extends to marketing Burt’s Bees organic baby formulas and “nature-based” supplements for infants and children. Burt’s Bees announcement offsets Q1 dips in domestic and international consumer health sales.
People On The Move: Appointments At UPSA, Bionorica And MHRA
The latest European consumer health people news: Sanofi Consumer Healthcare's Van Rycke named CEO of UPSA; Bionorica's global business head steps down; MHRA names its first chief safety officer.
Legislation
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Health & Legislation
Including Oxybenzone, Octinoxate On US Sunscreen Monograph Could Swing On Environmental Impact
FDA will prepare an environmental impact statement on sunscreen ingredients oxybenzone and octinoxate in light of questions on the ingredients’ impact on coral and coral reefs. It plans to complete the review prior to publishing final order for its OTC sunscreen ingredients monograph.
FTC Will Ask Congress To Sharpen Monetary Relief Authority Dulled By Supreme Court Ruling
Justice Breyer suggests FTC ask Congress to strengthen its enforcement rules. It is “free to ask Congress to grant it further remedial authority,” according to court opinion stating a rule the FTC has wielded for forty years to impose financial penalties doesn’t grant it authority to obtain equitable monetary relief.
Funding For US FDA Work On Cannabinoids Regulatory Pathway Drives Progress Only So Far
FDA is conducting lab testing on CBD products with funding in its FY2021 appropriations, says senior agency advisor Sharon Mayl. Some work planned work in the area has been delayed by the agency's response to COVID-19.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.